{
  "Country": "NL",
  "PICOs": [
    {
      "Population": "Patients with stage IV NSCLC (squamous and nonsquamous) with a PD-L1 tumor proportion score of 50% or greater",
      "Intervention": "New medicine under assessment",
      "Comparator": "Chemotherapy",
      "Outcomes": "Overall survival"
    },
    {
      "Population": "Patients with recurrent or stage IV squamous NSCLC",
      "Intervention": "New medicine under assessment",
      "Comparator": "Chemotherapy",
      "Outcomes": "Progression free survival"
    },
    {
      "Population": "Patients with metastatic nonsquamous NSCLC",
      "Intervention": "New medicine under assessment",
      "Comparator": "Chemotherapy",
      "Outcomes": "Overall survival and progression free survival"
    },
    {
      "Population": "Patients with ALK translocation",
      "Intervention": "New medicine under assessment",
      "Comparator": "Alectinib, brigatinib, lorlatinib",
      "Outcomes": "Progression free survival"
    },
    {
      "Population": "Patients with ALK fusion",
      "Intervention": "New medicine under assessment",
      "Comparator": "Crizotinib or ceritinib",
      "Outcomes": "Progression free survival"
    },
    {
      "Population": "Patients with inoperable locally advanced or metastatic NSCLC harboring a KRAS analogy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Chemotherapy (gemcitabine or docetaxel)",
      "Outcomes": "Overall survival"
    },
    {
      "Population": "Patients with ROS1+ NSCLC",
      "Intervention": "New medicine under assessment",
      "Comparator": "Entrectinib, lorlatinib",
      "Outcomes": "Overall response rate and median progression free survival"
    },
    {
      "Population": "Patients with stage II-III NSCLC harboring a common EGFR analogy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Chemotherapy",
      "Outcomes": "Overall survival and quality of life"
    },
    {
      "Population": "Patients with NSCLC and PD-L1 <50%",
      "Intervention": "New medicine under assessment",
      "Comparator": "Platinum-pemetrexed or carboplatin-paclitaxel-bevacizumab-atezolizumab",
      "Outcomes": "Overall survival and progression free survival"
    }
  ]
}